This is a preprint.
Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder
- PMID: 36824922
- PMCID: PMC9949170
- DOI: 10.21203/rs.3.rs-2580252/v1
Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder
Update in
-
Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder.Mol Psychiatry. 2023 Dec;28(12):5251-5261. doi: 10.1038/s41380-023-02149-1. Epub 2023 Jul 11. Mol Psychiatry. 2023. PMID: 37433967 Free PMC article.
Abstract
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N=2,367) and replicated in the combined PsyCourse (N=89) and BipoLife (N=102) studies. The associations of Li+PGS and lithium treatment response - defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P<����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������.
Conflict of interest statement
Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), and the Stanley Medical Research Institute. Michael Bauer has received grants from the Deutsche Forschungsgemeinschaft (DFG), and Bundesministeriums für Bildung und Forschung (BMBF), and served as consultant, advisor or CME speaker for the following entities: Allergan, Aristo, Janssen, Lilly, Lundbeck, neuraxpharm, Otsuka, Sandoz, Servier and Sunovion outside the submitted work. Sarah Kittel-Schneider has received grants and served as consultant, advisor or speaker for the following entities: Medice Arzneimittel Pütter GmbH and Shire/Takeda. Bernhard Baune has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Servier, the National Health and Medical Research Council, the Fay Fuller Foundation, the James and Diana Ramsay Foundation. Scott Clark has received grants and served as consultant, advisor or CME speaker for the following entities: Otsuka Austalia, Lundbeck Australia, Janssen-Cilag Australia, Servier Australia. Tadafumi Kato received honoraria for lectures, manuscripts, and/or consultancy, from Kyowa Hakko Kirin Co, Ltd, Eli Lilly Japan K.K., Otsuka Pharmaceutical Co, Ltd, GlaxoSmithKline K.K., Taisho Toyama Pharmaceutical Co, Ltd, Dainippon Sumitomo Pharma Co, Ltd, Meiji Seika Pharma Co, Ltd, Pfizer Japan Inc., Mochida Pharmaceutical Co, Ltd, Shionogi & Co, Ltd, Janssen Pharmaceutical K.K., Janssen Asia Pacific, Yoshitomiyakuhin, Astellas Pharma Inc, Wako Pure Chemical Industries, Ltd, Wiley Publishing Japan, Nippon Boehringer Ingelheim Co Ltd, Kanae Foundation for the Promotion of Medical Science, MSD K.K., Kyowa Pharmaceutical Industry Co, Ltd and Takeda Pharmaceutical Co, Ltd. Tadafumi Kato also received a research grant from Takeda Pharmaceutical Co, Ltd. Peter Falkai has received grants and served as consultant, advisor or CME speaker for the following entities Abbott, GlaxoSmithKline, Janssen, Essex, Lundbeck, Otsuka, Gedeon Richter, Servier and Takeda as well as the German Ministry of Science and the German Ministry of Health. Eva Reininghaus has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen and Institut Allergosan. Mikael Landén declares that, over the past 36 months, he has received lecture honoraria from Lundbeck and served as a scientific consultant for EPID Research Oy; no other equity ownership, profit-sharing agreements, royalties or patent. Kazufumi Akiyama has received consulting honoraria from Taisho Toyama Pharmaceutical Co, Ltd. In 2021, Jörg Zimmermann served as an advisor for Biogen concerning Aducanumab (Alzheimer`s Disease).The other authors have no other conflict of interest to disclose.
Figures



Similar articles
-
Association of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder.Mol Psychiatry. 2023 Dec;28(12):5251-5261. doi: 10.1038/s41380-023-02149-1. Epub 2023 Jul 11. Mol Psychiatry. 2023. PMID: 37433967 Free PMC article.
-
Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.Mol Psychiatry. 2021 Jun;26(6):2457-2470. doi: 10.1038/s41380-020-0689-5. Epub 2020 Mar 16. Mol Psychiatry. 2021. PMID: 32203155
-
Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients.Transl Psychiatry. 2021 Nov 29;11(1):606. doi: 10.1038/s41398-021-01702-2. Transl Psychiatry. 2021. PMID: 34845190 Free PMC article.
-
Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.J Affect Disord. 2018 Jun;233:92-99. doi: 10.1016/j.jad.2017.12.026. Epub 2017 Dec 22. J Affect Disord. 2018. PMID: 29310970 Review.
-
Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.CNS Drugs. 2013 Mar;27(3):165-73. doi: 10.1007/s40263-013-0040-7. CNS Drugs. 2013. PMID: 23378337 Free PMC article. Review.
References
-
- Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387(10027): 1561–1572. - PubMed
-
- DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1859–1922. - PMC - PubMed
-
- Walker S, Mackay E, Barnett P, Sheridan Rains L, Leverton M, Dalton-Locke C et al. Clinical and social factors associated with increased risk for involuntary psychiatric hospitalisation: a systematic review, meta-analysis, and narrative synthesis. Lancet Psychiatry 2019; 6(12): 1039–1053. - PMC - PubMed
-
- Cade JF. Lithium salts in the treatment of psychotic excitement. The Medical journal of Australia 1949; 2(10): 349–352. - PubMed
Publication types
Grants and funding
- R01 MH059556/MH/NIMH NIH HHS/United States
- R01 MH059535/MH/NIMH NIH HHS/United States
- R01 MH059567/MH/NIMH NIH HHS/United States
- R01 MH059545/MH/NIMH NIH HHS/United States
- P01 CA089392/CA/NCI NIH HHS/United States
- Z01 MH002810/ImNIH/Intramural NIH HHS/United States
- R01 MH059548/MH/NIMH NIH HHS/United States
- R01 MH059534/MH/NIMH NIH HHS/United States
- R01 MH059533/MH/NIMH NIH HHS/United States
- K02 DA021237/DA/NIDA NIH HHS/United States
- R01 MH059553/MH/NIMH NIH HHS/United States
- R01 MH060068/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous